Syros Pharmaceuticals Stock Analysis

Syros Stock Analysis Notes

About 76.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.07. Syros Pharmaceuticals had not issued any dividends in recent years. The entity had 1:10 split on the 19th of September 2022. Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Syros Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Syros Pharmaceuticals contact Conley Chee at 617 744 1340 or learn more at https://www.syros.com.

Syros Pharmaceuticals Investment Alerts

Syros Pharmaceuticals Upcoming and Recent Events

Syros Largest EPS Surprises

View All Earnings Estimates

Syros Pharmaceuticals Thematic Classifications

Syros Stock Institutional Investors

Note, although Syros Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Syros Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.73 M.

Syros Profitablity

Management Efficiency

Syros Pharmaceuticals has return on total asset (ROA) of (0.5988) % which means that it has lost $0.5988 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.7696) %, meaning that it created substantial loss on money invested by shareholders. Syros Pharmaceuticals' management efficiency ratios could be used to measure how well Syros Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.03 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Syros Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Debt To Assets is likely to gain to 0.27 in 2024, whereas Total Assets are likely to drop slightly above 147.5 M in 2024.

Technical Drivers

As of the 28th of November, Syros Pharmaceuticals has the Risk Adjusted Performance of (0.03), variance of 206.68, and Coefficient Of Variation of (2,062). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Syros Pharmaceuticals, as well as the relationship between them. Please validate Syros Pharmaceuticals risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Syros Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 0.27 per share. As Syros Pharmaceuticals appears to be a penny stock we also recommend to double-check its jensen alpha numbers.

Syros Pharmaceuticals Price Movement Analysis

Syros Pharmaceuticals Insider Trading Activities

Syros Pharmaceuticals Outstanding Bonds

Syros Pharmaceuticals Predictive Daily Indicators

Syros Pharmaceuticals Forecast Models

Syros Pharmaceuticals' time-series forecasting models are one of many Syros Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Syros Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Syros Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Syros shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Syros Pharmaceuticals. By using and applying Syros Stock analysis, traders can create a robust methodology for identifying Syros entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Syros analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Syros analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Syros Pharmaceuticals stock analysis indicators help investors evaluate how Syros Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Syros Pharmaceuticals shares will generate the highest return on investment. By understating and applying Syros Pharmaceuticals stock analysis, traders can identify Syros Pharmaceuticals position entry and exit signals to maximize returns.

When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.